Elliot M J, Cullen P M, Phillips C I
Br J Ophthalmol. 1975 Jun;59(6):296-300. doi: 10.1136/bjo.59.6.296.
Atenolol (Tenormin or I.C.I. 66082) is a new beta-adrenergic blocking drug, unique in being cardio-selective and in having no intrinsic sympathomimetic or membrane activity. In a controlled double-blind study, a single 50 mg oral dose produced a significant fall in ocular tension for about 7 hours in five patients with definite or suspected glaucoma. The average maximum fall was 35 per cent of the initial pressure; it occurred at 5 hours after oral ingestion. Accordingly neither intrinsic sympathomimetic nor membrane activity can account for all the ocular hypotensive effect of beta blockers in humans. The practical implications for treatment of glaucoma require longer-term investigations some of which are in progress.
阿替洛尔（氨酰心安或ICI 66082）是一种新型β-肾上腺素能阻滞剂，其独特之处在于具有心脏选择性，且无内在拟交感活性或膜活性。在一项对照双盲研究中，5例确诊或疑似青光眼患者口服50毫克单剂量该药后，眼压显著下降约7小时。平均最大降幅为初始眼压的35%；口服后5小时出现。因此，内在拟交感活性和膜活性均不能解释β受体阻滞剂对人体的全部降眼压作用。青光眼治疗的实际意义需要进行更长期的研究，其中一些研究正在进行中。
